Keywords:atrophic vulvovaginitis, vaginal index, depantol, revitaksa, methyluracilum
Atrophic vulvovaginitis is one of the most common pathological conditions at postmenopausal period. Vaginal mucosa atrophy observed in almost half of women 7–10 years after the cessation of menstruation and further their frequency reaches to 70–75%. Activation of atrophic of immune cells is characteristic for vulvovaginitis apoptosis which creates conditions for the development of secondary immunodeficiency.
The leading cause of vulvovaginal atrophic is aging lower estrogen levels resulting from ovarian failure. In addition, great importance in the development of pathological process belong to colonization resistance of vaginal mucosa.
Comparative analysis of depantol therapy, drugs and revitaksa and methyluracilum in suppositories was done to determine the clinical efficacy of depantol in atrophic vaginitis treatment. Depantol is a combined reparative, anti-inflammatory and antimicrobial drug containing chlorhexidine digluconate and panthenol.
The study included 79 women of menopausal age with a diagnosis of atrophic vaginitis. 27 of them were treated by depantol, 27 – use revitaksa, 25 – methyluracilum.
At the beginning of therapy, after completion and 2, 4 and 6 months after treatment was evaluated the vaginal index (elasticity, the volume of fluid in the vagina, pH, vaginal epithelium integrity and its moisture). To evaluate the immunostimulatory and regenerative properties of used medicines we determining the extent and nature of apoptotic processes in the immune cells of the peripheral blood of patients with atrophic vaginitis.
Use depantol helped restore vaginal index, normalization of vaginal microbial status and created conditions to eliminate the immunodeficiency. Revitaksa and methyluracilum unsignificantly improved vaginal index but did not cause significant reduction of apoptotic processes at vaginal atrophy.
According to the authors, the results of the study are important for women with menopausal atrophic vaginitises age and patients with the postcastration syndrome that on various reasons have contraindications or do not want to use estrogen therapy.
- Kravchenko, O.V. “Correction of early menopausal disorders in women with a history of uterine cancer.” Reproductive Endocrinology, 6(20) (2014): 45–47.
- Bachman, G.A., Notelovitz, M., Gonzalez, S.I. “Vaginal dryness in menopausal women: clinical characteristics and nonhormonal treatment.” Clin Prac Sexual, 7(1991): 25–32.
- Leiblum, S., Bachmann, G., Kemmann, E. “Vaginal atrophy in the postmenopausal woman, the importance of sexual activity and hormones.” JAMA, 249(2007): 2195–2198.
- Kira, E.F. Infections and Reproductive Health // Modern methods of diagnosis, therapy and prevention of urogenital infections. Moscow (2000): 22–25.
- Lang, W.R., Aponto, G.F. “Gross and microscopic anatomy of the aged female reproductive organs.” Clin Obstet Gynecol, 10(2007): 454–456.
- Semmens, I.P., Semmens, E.C., et al. “Effects of estrogen therapy on vaginal physiology during menopause.” Obstet Gynecol, 67(2008): 15–24.
- Semmens, I.P., Wagner, G. “Estrogen deprivation and vaginal function in postmenopausal women.” JAMA, 248(2004): 445–447.
- Gadieva, F.G. “Relationship immune and endocrine systems in women of reproductive age.” Obstetrics and Gynecology, 1(2001): 11–13.
- Wi Wond, I., Hoist, I., Kazberg, L.A. “A new methodological approach to the evaluation of quality of life in postmenopausal women.” Maturitas, 14(2008): 211–224.
- Baryshnikov, A.Y., Shishkin, Y.V. Immunological problems of apoptosis. Moscow. Editorial URSS (2002): 320 p.
- Luchnikov, E.F., Abrosimov, A.Y. Cell death (apoptosis). Moscow. Medicine (2008): 192 p.
How to Cite
Copyright (c) 2015 О. П. Танько, М. В. Самойлова, С. В. Коровай, О. Л. Черняк, І. С. Остапова
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.